DNA Lite
San Francisco, US · 3 known investors
Particella, Inc. (formerly DNAlite Therapeutics) is a preclinical biotechnology company developing an oral lipid nanoparticle platform to deliver nucleic acids, such as mRNA, to the intestinal epithelium. It focuses on oral mRNA medicines.
BiotechDeep Tech
Founders & leadership
MA
Mubhij AhmadNamed on SEC filing
DR
David RabukaNamed on SEC filing
TP
Timothy Paul DayNamed on SEC filing
Board
AC
Andrew Cain McClaryBoard director
DL
Drew LanzaBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$5.6M disclosed across 1 round · 2022
▶$5.6MraisedApr 2022 · 18 investors · BiotechnologyRule 506(b)
▶$5.6MraisedApr 2022 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mubhij AhmadExecutive Officer, Director
- David RabukaDirector
- Timothy Paul DayDirector
- Andrew Cain McClaryDirector
- Drew LanzaDirector
- Offering amount
- $8.9M
- Amount sold
- $5.6M
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does DNA Lite do?
- Particella, Inc. (formerly DNAlite Therapeutics) is a preclinical biotechnology company developing an oral lipid nanoparticle platform to deliver nucleic acids, such as mRNA, to the intestinal epithelium. It focuses on oral mRNA medicines.
- Who are DNA Lite's investors?
- DNA Lite's investors include Berkeley Catalyst, Blue Bear Ventures, KdT Ventures.
- How much funding has DNA Lite raised?
- DNA Lite has disclosed $5.6M raised across 1 round.
- Where is DNA Lite headquartered?
- DNA Lite is headquartered in San Francisco, US.